The bivalent mRNA boosters from Pfizer-BioNTech and Moderna were 48% effective against symptomatic infection from the predominant omicron subvariant (XBB/XBB.1.5) in persons aged 18-49 years according to early data published by the CDC nbcnews.com Submitted by shiruken t3_10lcgah on January 25, 2023 at 10:58 PM in science 75 comments 337
watabadidea t1_j5xsb7q wrote on January 26, 2023 at 8:08 AM So what is that in terms of actual incident rates? Medical interventions should be based on a cost/benefit analysis. If costs are reported as incident rates but benefits aren't, how can I compare the two adequately? Permalink 5
Viewing a single comment thread. View all comments